Crescent Biopharma, Inc. Cash Flow Conversion Efficiency
Crescent Biopharma, Inc. cash flow conversion efficiency. Based on the latest financial reports, Crescent Biopharma, Inc. (CBIO) has a cash flow conversion efficiency ratio of -0.119x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.46 Million) by net assets ($163.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Crescent Biopharma, Inc. (2011–2025)
Cash flow conversion efficiency of Crescent Biopharma, Inc. from 2011 to 2025. This chart illustrates how Crescent Biopharma, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Crescent Biopharma, Inc. stock price today for real-time trading data and today's change.
Crescent Biopharma, Inc. Cash Flow Conversion Ratio Explained
Crescent Biopharma, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Crescent Biopharma, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Crescent Biopharma, Inc. ranked by their cash flow conversion efficiency. Also see market cap of Crescent Biopharma, Inc. for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Soling Industrial Co Ltd
SHE:002766
|
0.034x |
|
Solid Power Inc
NASDAQ:SLDP
|
-0.017x |
|
Qingdao Topscomm Commun Inc
SHG:603421
|
0.017x |
|
Capital Bancorp
NASDAQ:CBNK
|
0.053x |
|
Ambassador Hotel Ltd
TW:2704
|
0.009x |
|
EV MOTORS, S.A.
MC:EBROM
|
N/A |
|
OPTHEA LTD (SP.ADR/8)
F:UKJ2
|
N/A |
|
CellaVision AB
ST:CEVI
|
0.058x |
Annual Cash Flow Conversion Efficiency for Crescent Biopharma, Inc. (2011–2025)
The table below shows the annual cash flow conversion efficiency of Crescent Biopharma, Inc. from 2011 to 2025. Review CBIO cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $203.01 Million | $-71.53 Million | -0.352x | -117.54% |
| 2024-12-31 | $-15.48 Million | $-31.10 Million | 2.009x | +321.26% |
| 2023-12-31 | $38.41 Million | $-34.88 Million | -0.908x | +16.10% |
| 2022-12-31 | $42.93 Million | $-46.46 Million | -1.082x | -53.61% |
| 2021-12-31 | $81.60 Million | $-57.49 Million | -0.704x | -130.19% |
| 2020-12-31 | $128.22 Million | $-39.24 Million | -0.306x | +9.22% |
| 2019-12-31 | $154.20 Million | $-51.98 Million | -0.337x | -59.85% |
| 2018-12-31 | $205.46 Million | $-43.33 Million | -0.211x | +15.20% |
| 2017-12-31 | $119.70 Million | $-29.77 Million | -0.249x | +70.47% |
| 2016-12-31 | $35.30 Million | $-29.73 Million | -0.842x | -313.57% |
| 2015-12-31 | $40.47 Million | $-8.24 Million | -0.204x | -141.64% |
| 2014-12-31 | $50.80 Million | $-4.28 Million | -0.084x | +98.42% |
| 2013-12-31 | $2.91 Million | $-15.54 Million | -5.345x | -539.33% |
| 2012-12-31 | $12.53 Million | $-10.47 Million | -0.836x | -151.03% |
| 2011-12-31 | $8.46 Million | $13.85 Million | 1.638x | -- |
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the develo… Read more